Mitochon Pharmaceuticals, a Blue Bell, Pa.-based developer of treatments for insidious diseases through the modulation of mitochondrial physiology, with applications to neurodegeneration, neuromuscular, and developmental diseases, completed a $1.6m funding round.
Backers included Ben Franklin Technology Partners and private investors.
The company intends to use the funds to advance its lead compound MP101, a mitochondrial targeted neuro-protective agent, into human studies, as well as, further develop MP201 for IND filing.
Co-founded in 2014 by Robert Alonso, CEO, and John Geisler, PhD., CSO, Mitochon develops MP101, a Mitochondrial modulator for Huntington’s, DMD and Battens disease, burn victims and epilepsy, and MP201, a mitochondrial modulator for Multiple Sclerosis, Stroke, Alzheimer’s and Parkinson’s.
FinSMEs
17/05/2016